|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DOCK7 |
Gene summary for DOCK7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DOCK7 | Gene ID | 85440 |
| Gene name | dedicator of cytokinesis 7 | |
| Gene Alias | DEE23 | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96N67 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85440 | DOCK7 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.34e-08 | -4.34e-01 | 0.0155 |
| 85440 | DOCK7 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.39e-03 | -3.67e-01 | -0.1808 |
| 85440 | DOCK7 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.23e-02 | -4.37e-01 | -0.1207 |
| 85440 | DOCK7 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.35e-04 | -3.49e-01 | -0.1464 |
| 85440 | DOCK7 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.70e-05 | -4.52e-01 | 0.096 |
| 85440 | DOCK7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.01e-11 | -4.62e-01 | 0.0674 |
| 85440 | DOCK7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.50e-14 | -5.18e-01 | 0.3005 |
| 85440 | DOCK7 | A001-C-207 | Human | Colorectum | FAP | 9.14e-04 | -1.97e-01 | 0.1278 |
| 85440 | DOCK7 | A015-C-203 | Human | Colorectum | FAP | 1.32e-29 | -4.26e-01 | -0.1294 |
| 85440 | DOCK7 | A015-C-204 | Human | Colorectum | FAP | 6.35e-05 | -2.80e-01 | -0.0228 |
| 85440 | DOCK7 | A014-C-040 | Human | Colorectum | FAP | 4.51e-05 | -4.02e-01 | -0.1184 |
| 85440 | DOCK7 | A002-C-201 | Human | Colorectum | FAP | 5.28e-17 | -4.07e-01 | 0.0324 |
| 85440 | DOCK7 | A002-C-203 | Human | Colorectum | FAP | 5.40e-05 | -1.05e-01 | 0.2786 |
| 85440 | DOCK7 | A001-C-119 | Human | Colorectum | FAP | 5.78e-07 | -3.83e-01 | -0.1557 |
| 85440 | DOCK7 | A001-C-108 | Human | Colorectum | FAP | 4.13e-17 | -2.78e-01 | -0.0272 |
| 85440 | DOCK7 | A002-C-205 | Human | Colorectum | FAP | 7.00e-22 | -3.06e-01 | -0.1236 |
| 85440 | DOCK7 | A001-C-104 | Human | Colorectum | FAP | 1.39e-03 | -1.41e-01 | 0.0184 |
| 85440 | DOCK7 | A015-C-005 | Human | Colorectum | FAP | 6.85e-07 | -3.17e-01 | -0.0336 |
| 85440 | DOCK7 | A015-C-006 | Human | Colorectum | FAP | 3.23e-19 | -5.02e-01 | -0.0994 |
| 85440 | DOCK7 | A015-C-106 | Human | Colorectum | FAP | 4.80e-13 | -2.17e-01 | -0.0511 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430874 | Colorectum | CRC | regulation of GTPase activity | 69/2078 | 348/18723 | 1.11e-06 | 6.69e-05 | 69 |
| GO:00615644 | Colorectum | CRC | axon development | 86/2078 | 467/18723 | 1.48e-06 | 8.12e-05 | 86 |
| GO:00181054 | Colorectum | CRC | peptidyl-serine phosphorylation | 61/2078 | 315/18723 | 9.88e-06 | 3.31e-04 | 61 |
| GO:00507673 | Colorectum | CRC | regulation of neurogenesis | 68/2078 | 364/18723 | 1.11e-05 | 3.62e-04 | 68 |
| GO:00182093 | Colorectum | CRC | peptidyl-serine modification | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
| GO:00435473 | Colorectum | CRC | positive regulation of GTPase activity | 49/2078 | 255/18723 | 8.67e-05 | 1.77e-03 | 49 |
| GO:00309001 | Colorectum | CRC | forebrain development | 66/2078 | 379/18723 | 1.36e-04 | 2.57e-03 | 66 |
| GO:00070974 | Colorectum | CRC | nuclear migration | 8/2078 | 20/18723 | 8.36e-04 | 1.04e-02 | 8 |
| GO:00519602 | Colorectum | CRC | regulation of nervous system development | 71/2078 | 443/18723 | 9.28e-04 | 1.14e-02 | 71 |
| GO:00016591 | Colorectum | CRC | temperature homeostasis | 32/2078 | 174/18723 | 2.81e-03 | 2.55e-02 | 32 |
| GO:00516474 | Colorectum | CRC | nucleus localization | 8/2078 | 24/18723 | 3.25e-03 | 2.81e-02 | 8 |
| GO:01061062 | Colorectum | CRC | cold-induced thermogenesis | 27/2078 | 144/18723 | 4.38e-03 | 3.47e-02 | 27 |
| GO:01201612 | Colorectum | CRC | regulation of cold-induced thermogenesis | 27/2078 | 144/18723 | 4.38e-03 | 3.47e-02 | 27 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
| GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DOCK7 | SNV | Missense_Mutation | c.1635C>G | p.Ile545Met | p.I545M | Q96N67 | protein_coding | deleterious(0.02) | possibly_damaging(0.582) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DOCK7 | SNV | Missense_Mutation | c.1793C>A | p.Ala598Asp | p.A598D | Q96N67 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | |
| DOCK7 | SNV | Missense_Mutation | c.1450G>T | p.Asp484Tyr | p.D484Y | Q96N67 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DOCK7 | SNV | Missense_Mutation | c.4728N>C | p.Glu1576Asp | p.E1576D | Q96N67 | protein_coding | tolerated(0.05) | possibly_damaging(0.666) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DOCK7 | SNV | Missense_Mutation | rs780945471 | c.2927C>T | p.Thr976Met | p.T976M | Q96N67 | protein_coding | tolerated(0.11) | benign(0.073) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
| DOCK7 | SNV | Missense_Mutation | c.4148G>T | p.Ser1383Ile | p.S1383I | Q96N67 | protein_coding | tolerated(0.08) | possibly_damaging(0.755) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| DOCK7 | SNV | Missense_Mutation | c.4054N>G | p.Ser1352Ala | p.S1352A | Q96N67 | protein_coding | tolerated(0.21) | benign(0.03) | TCGA-AR-A0TW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD | |
| DOCK7 | SNV | Missense_Mutation | c.3043N>G | p.Met1015Val | p.M1015V | Q96N67 | protein_coding | deleterious(0.01) | benign(0.036) | TCGA-AR-A1AX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DOCK7 | SNV | Missense_Mutation | novel | c.5660N>G | p.Ser1887Cys | p.S1887C | Q96N67 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DOCK7 | SNV | Missense_Mutation | novel | c.6305N>A | p.Arg2102Lys | p.R2102K | Q96N67 | protein_coding | tolerated(0.09) | benign(0.281) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |